[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342471-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342471-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pharmacokinetic-analysis-of-prognostic-factors-in-patients-with-advanced-stage-intrahepatic-cholangiocarcinoma-article","Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma - Article","","Study aimed to establish pharmacokinetic-based prognostic predictors for advanced-stage intrahepatic cholangiocarcinoma after capsule administration of a standardized Atractylodes lancea extract (AL, CMC-AL). Advanced patients received daily doses under three regimen groups or palliative care as control, followed by statistical evaluation using Cox proportional hazards and ROC methods. Total AL bioactivity and pharmacokinetic cut-offs were linked to progression-free survival and disease control rate, with defined therapeutic ranges. Findings support improving AL efficacy and guiding future phase 2B validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pharmacokinetic-analysis-of-prognostic-factors-in-patients-with-advanced-stage-intrahepatic-cholangiocarcinoma-article/342471/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pharmacokinetic-analysis-of-prognostic-factors-in-patients-with-advanced-stage-intrahepatic-cholangiocarcinoma-article/342471.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of this study in advanced-stage intrahepatic cholangiocarcinoma?","Question",{"text":63,"@type":64},"To identify prognostic factors based on pharmacokinetics of total AL bioactivity and to determine therapeutic ranges after CMC-AL capsule administration.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients grouped and dosed in the trial design?",{"text":68,"@type":64},"Group 1 received 1000 mg daily of CMC-AL for 90 days; Group 2 received 1000 mg daily for 14 days, then 1500 mg for 14 days, and 2000 mg for 62 days; Group 3 received palliative care.",{"name":70,"@type":61,"acceptedAnswer":71},"Which pharmacokinetic parameters were used to derive prognostic predictors?",{"text":72,"@type":64},"Cut-off values of AUC0-inf, Cmax, and Cavg were assessed using ROC, alongside Cox proportional hazard modeling, to link drug exposure to therapeutic outcomes such as PFS and DCR.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342471,1791225417,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma Following the Administration of Capsule Formulation of the Standardized Extract of Atractylodes lancea (Thunb) DC  \nIntegrative Cancer Therapies Volume 23: 1–12  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15347354231223967](DOI: 10.1177/15347354231223967)[ ](DOI: 10.1177/15347354231223967)[journals.sagepub.com/home/ict](journals.sagepub.com/home/ict)  \nTeerachat Saeheng, PhD 1, Juntra Karbwang, PhD, MD 1,  \nAnurak Cheomung, PhD 1, Nisit Tongsiri, MD2, Tullayakorn Plengsuriyakarn, PhD 1, and Kesara Na-Bangchang, PhD 1  \nAbstract  \nBackground: A statistical model is essential in determining the appropriate predictive indicators for therapies in many types of cancers. Predictors have been compared favorably to the traditional systems for many cancers. Thus, this study has been proposed as a new standard approach. A recent study on the clinical efficacy of Atractylodes lancea (Thunb) DC. (AL) revealed the higher clinical benefits in patients with advanced-stage intrahepatic cholangiocarcinoma (ICC) treated with AL compared with standard supportive care. We investigated the relationships between clinical efficacy and pharmacokinetic parameters of serum bioactivity of AL and its active constituent atractylodin and determined therapeutic ranges. Methods: Group 1 of advanced-stage ICC patients received daily doses of 1000 mg of standardized extract of the capsule formulation of AL (CMC-AL) for 90days. Group 2 received daily doses of 1000 mg of CMC-AL for 14days, followed by 1500 mg for 14days, and 2000 mg for 62days. Group 3 (control group) received palliative care. Cox proportional hazard model and Receiver Operating Characteristic (ROC) were applied to determine the cut-off values of AUC0-inf, Cmax, and Cavg associated with therapeutic outcomes. Number needed to treat (NNT) and relative risk (RR) were also applied to determine potential predictors. Results: The AUC0-inf of total AL bioactivity of >96.71 µg hour/ml was identified as a promising predictor of disease prognosis, that is, progression-free survival (PFS) and disease control rate (DCR). Cmax of total AL bioactivity of >21.42 was identified as a predictor of the prognosis of survival. The therapeutic range of total AL bioactivity for PFS and DCR is 14.48 to 65.8µg/ml, and for overall survival is 10.97 to 65.8µg/ml. Conclusions: The predictors of ICC disease prognosis were established based on the pharmacokinetics of total AL bioactivity. The information could be exploited to improve the clinical efficacy of AL inpatients with advanced-stage ICC. These predictors will be validated in a phase 2B clinical study.  \nTrial Registration: TCTR20210129007 ([TCTR: www.clinicaltrials.in.th](TCTR: www.clinicaltrials.in.th)).  \nKeywords  \nprognostic factors, advanced intrahepatic cholangiocarcinoma, therapy, biliary tract cancer, progression-free survival, disease control rate, tumor progression, overall survival  \nSubmitted June 9, 2023; revised October 31, 2023; accepted December 15, 2023  \nBackground  \nIntrahepatic cholangiocarcinoma (ICC), a biliary tract cancer, accounts for 20% of primary liver cancers.1 It is recognized as a deadly gastrointestinal cancer with a poor disease prognosis due to the lack of effective biomarkers for early  \ndiagnosis and effective treatment. With advanced disease, patients receiving first-line chemotherapy have a 5-year overall survival (OS) rate of lower than 20% .1 High rate resistance of ICC to first-line chemotherapy results in disease progression among the treated patients.2 Research and  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons AttributionNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/li","cbCaigjpc1HtOYnI","https://ap.wps.com/l/cbCaigjpc1HtOYnI","pdf",1189073,12,"English","# Background\n## Rationale for prognostic biomarkers and pharmacokinetic evaluation\n# Methods\n## Study design and patient groups\n## Endpoints, ROC cut-offs, and statistical models\n# Results\n## Predictive cut-off values and therapeutic ranges\n# Conclusions\n## Clinical implications and planned validation","[{\"question\":\"What was the purpose of this study in advanced-stage intrahepatic cholangiocarcinoma?\",\"answer\":\"To identify prognostic factors based on pharmacokinetics of total AL bioactivity and to determine therapeutic ranges after CMC-AL capsule administration.\"},{\"question\":\"How were patients grouped and dosed in the trial design?\",\"answer\":\"Group 1 received 1000 mg daily of CMC-AL for 90 days; Group 2 received 1000 mg daily for 14 days, then 1500 mg for 14 days, and 2000 mg for 62 days; Group 3 received palliative care.\"},{\"question\":\"Which pharmacokinetic parameters were used to derive prognostic predictors?\",\"answer\":\"Cut-off values of AUC0-inf, Cmax, and Cavg were assessed using ROC, alongside Cox proportional hazard modeling, to link drug exposure to therapeutic outcomes such as PFS and DCR.\"}]","Pharmacokinetic Analysis of Prognostic Factors in Patients With Advanced-Stage Intrahepatic Cholangiocarcinoma - Article | PDF",1790046729,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/431e2b7e723858d08ab6999b4b3540e0.webp",983,1276,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/764ff178774d3beb05074874f6308b52.webp",982,1275,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/799e6def07dc198881f70f45f0cbea20.webp",981,1273,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f501c2d315abad8bfe3416e519b0129c.webp",980,1272]